

9th Meeting on External Quality Assessment in Molecular Pathology

Official annual meeting of IQN PATH

Naples, May 14-15, 2020

Venue: Grand Hotel Oriente, Via Armando Diaz, 44, 80134 Napoli

PRELIMINARY PROGRAMME

Thursday, May 14, 2020

09:00 - 09:30 **Welcome and Opening** - N. Normanno, S. Cinieri, A. Sapino, G. Botti. A. Bianchi

09:30 - 11:00 **Emerging Biomarkers 1: Gene Fusions** - Chairs S. Patton, N. Normanno

The current status of development of new biomarkers and drugs will be presented. The implications for EQA programs will be discussed, with the aim to propose common initiatives for the standardization of EQA schemes.

09:30 - 09:45 NTRK - A. Sartore Bianchi

09:45 - 10:00 RET - G. Curigliano

10:00 - 10:15 FGFR - L. Rimassa

10:15 - 10:30 The IQN Path EQA Scheme for Fusions - S. Patton

10:30 - 11:00 Discussion

11:00 - 11:30 Coffee break

11:30 - 13:15 **PD-L1 Testing: Current State and Future Developments** - Chairs: J. Qi, E. Torlakovic

This session will focus on the status of PD-L1 testing, with particular regards to implications for EQA schemes.

11:30 - 11:45 Deconstructing PT for PD-L1: Purpose-based EQA - S. Nielsen

11:45 - 12:00 Report on CIQC/IQN Path Digital Slide PD-L1 initiative - E. Torlakovic

12:00 - 12:15 CAP-ACP Guidelines for PD-L1 Testing: Relevance to PT - C. Cheung

12:15 - 12:45 Report on Current PD-L1 Modules from all Academic Members

12:45 - 13:15 Discussion Focused on the Harmonization of EQA Methodology and terminology

13:15 - 14:30 Lunch

14:30 - 15:45 **Emerging Biomarkers 2: HRD** – Chairs: E. Rouleau, S. Deans

The current status of development of new biomarkers and drugs will be presented. The implications for EQA programs will be discussed, with the aim to propose common initiatives for the standardization of EQA schemes.

14:30 - 14:45 PARP Inhibitors and HRD in Ovarian Cancer - G. Daniele

14:45 - 15:00 Current Status of PARP Inhibitors Beyond Ovarian Cancer - E. Bria

15:00 - 15:15 The ENGOT Initiative for HRD Testing - E. Pujade-Lauraine

15:15 - 15:45 Discussion: Focus on EQA Issues

15:45 - 16:45 **Technology Improvements** - Chairs: C. Pinto, A. Russo

16:45 - 17:00 Tea break

17:00 - 18:00 **General Meeting IQN Path** (open to all IQN Path members)

Friday, May 15, 2020

09:00 - 10:00 **Update on IQN Path Projects** - Chairs E. Torlakovic, J. Qi

09:00 - 09:10 Tumor Mutation Burden - F. Fenizia

09:10 - 09:20 Liquid Biopsy - S. Deans

09:20 - 09:30 Update of Recommendations for EQA Schemes - E. Dequecker

09:30 - 09:40 Harmonization of Terminology and Methodology for Biomarker PT - E. Torlakovich

09:40 - 10:00 Discussion on next steps

10:00 - 11:15 **The IQN Path – EFPIA Joint Project on the Status of Biomarker Testing in Europe** - Chairs N. Normanno, H. Moch

In this session the preliminary findings of the IQN Path – EFPIA project on biomarker testing in Europe will be discussed.

10:00 - 10:15 Outline and Aims - N. Normanno

10:15 - 10:30 Preliminary Findings - A. Wolf

10:30 - 10:45 The Patients' Survey - K. Apostolidis/F. De Lorenzo

10:45 - 11:15 Guided Discussion with Representatives of AIOM, ESMO, IARC, EMA, IQN Path Members, EFPIA, ECPC

11:15 - 11:45 Coffee break

11:45 - 13:00 **Restricted Session of IQN Path Partners on Next Projects**

13:00 - 14:00 Lunch